MARKET

KROS

KROS

Keros Therapeutics, Inc.
NASDAQ
11.33
+0.05
+0.44%
After Hours: 11.33 0 0.00% 19:30 10/26 EDT
OPEN
11.30
PREV CLOSE
11.28
HIGH
11.51
LOW
11.20
VOLUME
112.41K
TURNOVER
--
52 WEEK HIGH
22.55
52 WEEK LOW
9.69
MARKET CAP
224.64M
P/E (TTM)
-3.0597
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KROS last week (1019-1023)?
Weekly Report · 17h ago
Weekly Report: what happened at KROS last week (1012-1016)?
Weekly Report · 10/19 09:59
Weekly Report: what happened at KROS last week (1005-1009)?
Weekly Report · 10/12 10:03
Weekly Report: what happened at KROS last week (0928-1002)?
Weekly Report · 10/05 10:02
Keros Therapeutics Advances DMD Trial for KER-065, Keeping Rare Disease Upside in Play
TipRanks · 09/30 16:31
Keros Therapeutics earns milestone for Phase 3 myelofibrosis trial
TipRanks · 09/29 12:28
Keros Therapeutics to receive $20M development milestone payment from Takeda
TipRanks · 09/29 12:05
Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial
Benzinga · 09/29 12:04
More
About KROS
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Webull offers Keros Therapeutics Inc stock information, including NASDAQ: KROS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KROS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KROS stock methods without spending real money on the virtual paper trading platform.